Insmed (INSM)

Common Shares
Sell: $165.10|Buy: $168.66|Change: 2.57 (1.57%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

Company profile

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Address

700 US Highway 202/206
Bridgewater
NJ
USA
08807


Telephone

+1 908 977-9900


Sector 

Healthcare


Previous key dates

NameKey Date
Insmed Inc Third Quarter Earnings Conference Call for 20252025-10-30T08:00:00
Insmed Inc Third Quarter Earnings Results for 20252025-10-30T00:00:00
Morgan Stanely 23rd Annual Global Healthcare Conference2025-09-09T16:50:00
Wells Fargo 2025 Healthcare Conference2025-09-05T08:00:00
Insmed Inc Second Quarter Earnings Conference Call for 20252025-08-07T08:00:00
Insmed Inc Second Quarter Earnings Result for 20252025-08-07T00:00:00
2025 Goldman Sachs Annual Global Healthcare Conference2025-06-11T09:20:00
Insmed Phase 2b Study of TPIP in PAH Topline Results2025-06-10T08:00:00
Insmed Inc Annual General Meeting for 20252025-05-15T09:00:00
BofA Securities 2025 Health Care Conference2025-05-13T14:20:00
Insmed Inc First Quarter Earnings Conference Call for 20252025-05-08T08:00:00
Insmed Inc First Quarter Earnings Results for 20252025-05-08T00:00:00
Leerink Partners Global Healthcare Conference2025-03-11T08:00:00
45th Annual TD Cowen Healthcare Conference2025-03-03T09:10:00
Insmed Inc Fourth Quarter Earnings Conference Call for 20242025-02-20T08:00:00
Insmed Inc Fourth Quarter Earnings Result for 20242025-02-20T00:00:00
Insmed Inc Annual Report for 20242025-02-20T00:00:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-13T15:00:00
Nasdaq 51st Investor Conference2024-12-11T05:30:00
Evercore ISI HealthCONx Conference2024-12-04T11:15:00
Jefferies London Healthcare Conference2024-11-21T08:30:00
Wolfe Research Healthcare Conference2024-11-20T08:00:00
UBS Global Healthcare Conference2024-11-12T14:45:00
Guggenheim's Inaugural Healthcare Innovation Conference2024-11-11T13:00:00
Insmed Inc Third Quarter Earnings Conference Call for 20242024-10-31T08:00:00
Insmed Inc Third Quarter Earnings Results for 20242024-10-31T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.